TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who received at least one dose of either Corifollitropin Alfa or~Puregon®/Follistim® AQ Cartridge in Base Trial P05787 (NCT00696800);~* Ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in Base Trial P05787 (NCT00696800);~* Able and willing to give written informed consent.~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- Mothers Corifollitropin Alfa 150 µg (Type: None): Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles \>= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
- Mothers recFSH 200 IU (Type: None): Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles \>= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mizone vs Water for Bowel Preparation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients age between 18-75 years old requiring colonoscopy and willing to participate in this study.~Exclusion Criteria:~1. Patients with constipation;~2. Patients with congestive heart failure;~3. Patients with a history of kidney disease;~4. Patients with a history of poor intestinal preparation;~5. Pregnant / lactating women;~6. Patients without informed consent;~7. Allergic or intolerant to any research drug;~8. Patients with severe gastrointestinal diseases, such as intestinal obstruction or perforation, active ulcerative colitis, toxic colitis and toxic megacolon;~9. Patients with a history of inflammatory bowel disease;~10. Significant electrolyte anomalies, including phosphorus, sodium, potassium, calcium, chloride and magnesium;~11. History of colorectal resection；~12. Patients with diabetes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PEG-Mizone prep (Type: EXPERIMENTAL): The evening before the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 60g Polyethylene Glycol (PEG-4000) with 0.6L Mizone+0.4L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: The patients who are randomized to the  PEG-Mizone prep  arm will drink single dose of 120g Polyethylene Glycol (PEG-4000) with 1.2L Mizone+0.8L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
- PEG-ELS prep (Type: ACTIVE_COMPARATOR): The evening before the colonoscopy: In the PEG-ELS prep group, all the patients drink single dose of 60g Polyethylene Glycol (PEG-4000) with 1L water at a rate of 250 ml every 15 min.~On the day of the colonoscopy: all the patients drink single dose of 120g Polyethylene Glycol (PEG-4000) with 2L water 4-6 h before colonoscopy at a rate of 250 ml every 15 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Documented HIV-1 infection~* Initiation of ART through a government-sponsored ART program at least six months prior~* Undetectable HIV viral load (\< 400 copies/mL)~* CD4 count \> 250/mm3~* TS prophylaxis prescribed for at least the previous 2 months~* Intention to remain in the study area until the end of the study period~* Informed consent from participant~* Female study volunteers of reproductive potential must have a negative urine pregnancy test performed within 20 days before randomization.~* Female study volunteers of reproductive potential who participate in sexual activity that could lead to pregnancy must use contraception (male or female condoms, diaphragm or cervical cap with spermicide, intrauterine device, or hormone-based contraceptive) while receiving their assigned study drug and for one month after stopping the medications.~Exclusion Criteria:~* Severe acute illness (defined as requiring hospitalization at the time of screening or other conditions such as laboratory abnormalities as determined by the investigators)~* Chronic treatment (requiring therapy for \> 14 days) or secondary prophylaxis (for toxoplasmosis, Pneumocystis pneumonia, or tuberculosis for example) with any drug with antimalarial or antibacterial activity~* History of hypersensitivity to antifolate drugs or CQ~* Laboratory exclusion criteria~* Hemoglobin \< 8.0 gm/dL~* Platelet count \< 50,000/mm3~* Absolute granulocyte count \< 500/mm3~* Serum alanine aminotransferase (ALT) concentration \> 210 U/L for men, \>160 U/L for women~* Serum creatinine concentration \> 3.3mg/dl (291.7µmol/L) for men, and \> 2.7mg/dl (238.7µmol/L) for women)~* History of visual field or retinal changes~* History of preexisting auditory damage~* History of porphyria~* History of psoriasis~* History of liver disease~* History of seizure disorder~* History of glucose-6-phosphate dehydrogenase (G6PD) deficiency~* History of ECG and cardiac conduction abnormality or cardiomyopathy~* History of myopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care Prophylaxis (TS) (Type: ACTIVE_COMPARATOR): Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
- Chloroquine (CQ) prophylaxis (Type: EXPERIMENTAL): Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
- Discontinuation of standard of care (Type: NO_INTERVENTION): Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 and older~* Migraine for more than three months, that fail to respond to two or more major anti-migraine drug, meeting criteria of chronic migraine~Exclusion Criteria:~* Age below 18~* Pregnant or may become pregnant~* Disease of neuromuscular junction or drugs that affect N-M junction~* Allergy to Botox~* Previous use of Botox for migraine by similar methodology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
- Botox (Type: ACTIVE_COMPARATOR): Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients admitted for acute coronary syndrome or acute myocardial infarction requiring active treatment with aspirin clopidogrel and (enoxaparin or thrombolytics.)~Exclusion Criteria:~* known active peptic ulcer disease or gastrointestinal within 8 wk~* known iron deficiency anemia with Hb \< 10 gm/dl~* mechanical ventilation~* active cancer, liver cirrhosis, end-stage renal failure~* life expectancy \< 1 yr~* known allergic to aspirin, clopidogrel, enoxaparin famotidine or esomeprazole~* pregnancy, lactation, child-bearing potential in the absence of contraception,~* co-prescription of NSAID, corticosteroid, or warfarin~* non-oral feeding or impaired GI absorption e.g. vomiting~* already on proton pump inhibitor for \> 1 day or another clinical trial drug for ulcer disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): oral esomeprazole 20 mg daily
- 2 (Type: ACTIVE_COMPARATOR): oral famotidine 40mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Secretin Activates Human Brown Fat and Induces Satiation.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy normal weight~Exclusion Criteria:~* cardiovascular disease, diabetes~* smoking

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Secretin study (Type: EXPERIMENTAL): PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo cold exposure PET scanning once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Older Adults With Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acute lymphoblastic leukemia, excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14)(q24;q32), t(8;22), or t(2;8).~* Patients with mature B-cell ALL will be removed from the protocol as soon as the diagnosis is made and should be treated on a B-cell leukemia protocol.~* Patients with lymphoblastic lymphoma are also eligible~* No prior anti-leukemic therapy except \<1 week of steroids, and/or emergent radiation therapy to the mediastinum, or hydroxyurea or emergent leukopheresis. Longer steroid use for diseases other than leukemia is permitted.~* Age 51-75 years~* Ejection fraction \> 45%~* Creatinine \< 2.0 mg/dl~* Total bilirubin \< 3.0 mg/dl~* ECOG (Eastern Cooperative Oncology Group) Performance Status of 0, 1, 2~* Non-pregnant and non lactating~Exclusion Criteria:~* Known HIV positive~* Comorbid medical condition, in the investigator's opinion, would make participation in this trial and adherence to the protocol guidelines difficult~* Active psychiatric or mental illness making informed consent or careful clinical follow-up unlikely

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): All patients treated on same arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~* Healthy male /or female subjects,~* aged 18 to 65 years old,~* with LDL-C \> 130 mg/dL~* not receiving lipid lowering therapy.~Exclusion criteria:~* Healthy subjects with history or presence of clinically relevant illness.~* Subjects currently taking statins, ezetimibe or fenofibrate.~* The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Alirocumab + Ezetimibe Placebo (Type: EXPERIMENTAL): Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
- Alirocumab + Ezetimibe (Type: EXPERIMENTAL): Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
- Alirocumab + Fenofibrate (Type: EXPERIMENTAL): Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myopia Control by Combining Auricular Acupoint and Atropine Eyedrops

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all included patients, age from 6 to 15 years, had myopia (spherical equivalent \> -0.5 D) after cycloplegic refraction,~* The astigmatism and anisometropia were less than 2.0 D,~* IOP was less than 21 mmHg.~Exclusion Criteria:~* the presence of related disease such as infection, ulceration, eyelid disease, ocular and auricular disorders,~* individuals with amblyopia or strabismus,~* individuals received any other therapies in the period of study,~* individuals suffering some sort of haemostasis disorder,~* individuals did not follow the treatment (eyedrops and/or stimulation of auricular acupoints) over seven days

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Participants with type 2 diabetes mellitus.~* Participants on standard of care basal insulin therapy administered once or twice daily, as per labeling for at least 6 months prior to screening visit, with or without other antidiabetics approved for using with insulin.~* Glycated hemoglobin (HbA1c) between 7.5% (58 mmol/mol) and 10% (86 mmol/mol) inclusive, during screening.~* Fasting plasma glucose values above 130 mg/dL.~Exclusion criteria:~* Unstable basal insulin regimen in the last 8 weeks prior to screening visit (ie, type of insulin and time/frequency of the injection, insulin doses \[variation more than ±20%\]).~* Treatment with insulin other than basal insulin: mixed insulin (premixes), rapid insulin, fast acting insulin analogues in the last 6 months before screening visit (use ≤10 days in relation to hospitalization or an acute illness is accepted).~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (U300) (Type: EXPERIMENTAL): Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant must be healthy (in the physician's clinical judgment and as confirmed by medical records, and physical examination at screening).~* Willing to give informed consent, and answer short questionnaires on past exposure to COVID-19 and post-vaccination reactogenicity.~* Willing to comply with the requirements of the protocol.~Exclusion Criteria:~* Participant shows signs of an acute illness (excluding minor illnesses such as diarrhea or mild upper respiratory tract infection).~* Participant has a positive laboratory-confirmed test result for SARS-CoV-2 infection at screening.~* Deemed by investigators to be unlikely to complete study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sputnik V Vaccinees (Type: None): Participants (healthy adults aged \>=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HBeAg positive/negative CHB with blood HBVDNA≥10\^5 copies/mL and elevated ALT~* Nucleoside and nucleotide naïve CHB subjects. Previous lamivudine treatment is allowed in less than 10% of the total study population~Exclusion Criteria:~* subjects with hepatocellular carcinoma (HCC) potential or decompensated liver disease~* subjects with acute liver disease due to other causes~* subjects with medication history of immunosuppressive therapy, immunomodulatory therapy, systemic cytotoxic agents, chronic antiviral agents including Chinese herbal medicines known to have activity against HBV (e.g., lamivudine, hepatitis B immunoglobulin (HBIg)) within the previous 6 months prior to randomisation into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- A (TDF tablets) (Type: EXPERIMENTAL): Tenofovir disoproxil fumarate (TDF) tablets
- B (ADV tablets) (Type: ACTIVE_COMPARATOR): Adefovir dipivoxil (ADV) tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete